We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

By LabMedica International staff writers
Posted on 25 Apr 2025
Print article
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around 100 proteins that remove ubiquitin from a variety of substrates. Widely involved in the regulation of cellular processes including cell proliferation, autophagy, DNA damage repair, and immune response – DUBs have been implicated in a range of human diseases and consequently are attractive targets for potential therapeutic intervention via the development of suitable inhibitors and modulators. Now, a new range of DUB enzyme assay kits can accelerate routine DUB activity assays without compromising data quality.

AMS Biotechnology (Amsbio, Abingdon, England has launched a new range of DUB enzyme assay kits supplied in a convenient and easy-to-use 96-well assay format. These ready-to-use kits require minimal setup and no need for substrate preparation. The new kits are based on ubiquitin derivatives conjugated with various fluorophores that enable sensitive and specific detection using a microplate reader at an excitation wavelength of 485 nm and an emission wavelength of 535 nm. The range includes kits tailored to individual DUB enzymes such as BAP1, USP7, and UCHL1, enabling researchers to precisely profile activity or screen inhibitors against disease-relevant targets.

Designed to quickly measure deubiquitinase activity or inhibitor screening in purified enzyme systems and cell-based models – these new assay kits come optimized for both kinetic and endpoint analysis. Supplied in an industry standard 96-well microplate format these DUB enzyme assay kits are high throughput screening compatible and ready-to-use by academic, biotech and pharma researchers. The areas of research that may benefit from these kits include cancer tumor suppression and cell cycle regulation; neurodegenerative diseases, such as Parkinson’s, via mitochondrial and protein clearance pathways and immune system function and inflammation, where DUBs regulate cytokine signaling and innate immunity.

Related Links:
Amsbio

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.